Financials data is unavailable for this security.
View more
Year on year Biotage AB had net income fall -8.21% from 268.00m to 246.00m despite a 19.54% increase in revenues from 1.57bn to 1.87bn.
Gross margin | 62.90% |
---|---|
Net profit margin | 11.98% |
Operating margin | 16.83% |
Return on assets | 5.08% |
---|---|
Return on equity | 6.64% |
Return on investment | 5.87% |
More ▼
Cash flow in SEKView more
In 2023, Biotage AB increased its cash reserves by 34.69%, or 153.00m. The company earned 284.00m from its operations for a Cash Flow Margin of 15.17%. In addition the company generated 35.00m cash from investing, though they paid out 142.00m more in financing than they received.
Cash flow per share | 5.42 |
---|---|
Price/Cash flow per share | 33.38 |
Book value per share | 47.36 |
---|---|
Tangible book value per share | 6.26 |
More ▼
Balance sheet in SEKView more
Current ratio | 1.88 |
---|---|
Quick ratio | 1.14 |
Total debt/total equity | 0.067 |
---|---|
Total debt/total capital | 0.0628 |
More ▼
Growth rates in SEK
Year on year, growth in dividends per share remained flat while earnings per share excluding extraordinary items fell by -17.90%. Additionally when measured on a five year annualized basis, dividend per share growth is below the industry average relative to its peers, while earnings per share growth is in-line with the industry average.
Div yield(5 year avg) | 0.75% |
---|---|
Div growth rate (5 year) | 1.30% |
Payout ratio (TTM) | 51.21% |
EPS growth(5 years) | 5.12 |
---|---|
EPS (TTM) vs TTM 1 year ago | -3.58 |
More ▼